Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.57 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | ATR | Q13535 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082198 | 0.94 | GRM5 (0.58) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL14082162 | 0.93 | GRM5 (0.57) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL21477359 | 0.91 | TRPV1 (0.53) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL14082175 | 0.90 | TRPV1 (0.54) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL14082232 | 0.88 | ATR (0.58) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL7936347 | 0.84 | DRD2 (0.50) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL14082188 | 0.83 | SIGMAR1 (0.67) | MEN1KMT2ASMN1; SMN2MCHR1 | |
| SCHEMBL14082229 | 0.80 | KMT2A (0.53) | KMT2ATRPV1HPGDSMCHR1 | |
| SCHEMBL2979351 | 0.79 | RAB9A (1.00) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL14082343 | 0.79 | MAPKAPK2 (0.54) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | MEN1 4218/4885NPC1 1061/4885RAB9A 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.